Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension

• Published in: Journal of the American College of Cardiology Vol. 83; no. 4; pp. 473 - 484
• Main Authors: Grünig, Ekkehard, Jansa, Pavel, Fan, Fenling, Hauser, Jakob A., Pannaux, Matthieu, Morganti, Adele, Rofael, Hany, Chin, Kelly M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 30.01.2024
• Subjects: Cardiovascular; Combined Modality Therapy; Endothelin Receptor Antagonists; Humans; macitentan; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyrimidines; randomized controlled trial; single-tablet (fixed-dose) combination therapy; Sulfonamides; Tablets; Tadalafil; PDE5i; tadalafil; AE; CL; single-tablet (fixed-dose) combination therapy; PVR; randomized controlled trial; WHO FC; NT-proBNP; macitentan; ERA; M/T FDC; PAH; pulmonary arterial hypertension; 6MWD; World Health Organization functional class; adverse event; 6-minute walk distance; confidence limit; phosphodiesterase 5 inhibitor; macitentan and tadalafil fixed-dose combination; endothelin receptor antagonist; pulmonary vascular resistance; N-terminal pro-brain natriuretic peptide

Endothelin receptor antagonist (ERA) and phosphodiesterase 5 inhibitor (PDE5i) combination therapy is recommended for low-/intermediate-risk pulmonary arterial hypertension (PAH) patients. A fixed-dose combination of the ERA macitentan and PDE5i tadalafil (M/T FDC) in a once-daily, single tablet wou...